On January 21, 2022 the U.S. Food and Drug Administration (FDA) approved SKYRIZI® (risankizumab-rzaa), an interleukin-23 inhibitor, for the treatment of active psoriatic arthritis (PsA) in adults. 
This approval is based on findings from the KEEPsAKE-1 and KEEPsAKE-2 studies, which evaluated safety and efficacy among adult patients with PsA. In both Phase 3 studies, SKYRIZI® met the primary endpoint of ACR20 response at week 24 compared to placebo and demonstrated significant improvements across several other manifestations of PsA, including swollen, tender, and painful joints. 
The dosing regimen for SKYRIZI® is similar with to that for patients with moderate-to-severe psoriasis. It is a single 150 mg subcutaneous injection four times a year (after two starter doses at weeks 0 and 4) – and can be administered alone or in combination with DMARDs. 
Skyrizi is one of more than a dozen systemic agents approved by the FDA for the treatment of psoriatic disease. For more information on biologics, visit the NPF Biologics resources.